Biogen Inc. is a global biotechnology company headquartered in Cambridge, Massachusetts. Founded in 1978 and combined with IDEC Pharmaceuticals in 2003 (renamed Biogen in 2015), the company focuses on neurological and neurodegenerative diseases. It discovers, develops, manufactures, and commercializes biologic and small‑molecule medicines.
Biogen’s portfolio and pipeline address multiple sclerosis, spinal muscular atrophy, amyotrophic lateral sclerosis, Alzheimer’s disease, and related neuroimmune conditions. Its operations span discovery research, process development, clinical trials, and large‑scale biologics manufacturing in the US and Europe, supported by collaborations with academic and industry partners. Biogen’s work involves advanced bioprocessing, cell culture, and protein engineering, linking it to suppliers of specialty chemicals, materials, and analytical services across the life‑sciences value chain.
chemXplore tracks 1 project involving Biogen.
Biogen's role on them: Owner, Investor / Financier, Developer, and Offtaker.
Gazyva achieved sustained remission in young nephrotic syndrome patients, reducing steroid use. No new safety issues. Data to be shared with health authorities.
Brett Icahn joins IFF's Audit and Transaction Committees, while Richard Mulligan joins the Innovation Committee, following a cooperation agreement with Icahn Capital.
FDA approves Gazyva for lupus nephritis, showing superior results in trials, offering a new treatment option to prevent kidney disease progression.
